## Attorney Docket No. NASH-001/03US

**PATENT** 

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on ovember 4, 2003.

Vladimir. Skliba

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Thomas M. VAUGHN et al.

Examiner:

Unassigned

Serial No.:

10/601,314

Art Unit:

1614

Filed:

June 20, 2003

Confirmation No.:

6959

For:

METHODS OF MAKING AND USING THEAFLAVIN, THEAFLAVIN-3-

GALLATE, THEAFLAVIN-3'-GALLATE AND THEAFLAVIN 3,3'-

DIGALLATE AND MIXTURES THEREOF

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

## Transmitted herewith are:

- Information Disclosure Statement under 37 CFR §1.97(b) 1.
- 2. PTO/SB/08A
- 3. **PCT Search Report**
- 4. 8 references (A4-A10 and B1)
- 5. Return receipt postcard

In accordance with 37 C.F.R. §1.97(b), no fee for submission of the IDS is required.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 03-3117.

Dated: November 4, 2003

Respectfully submitted,

COOLEY GODWARD LLP

Cooley Godward LLP ATTN: Patent Group Five Palo Alto Square 3000 El Camino Real Palo Alto, CA 94306-2155

Tel: (650) 843-5000

Fax: (650) 857-0663

By:

Sunil K. Singh

Reg. No. 45,298

Attorney Docket No. NASH-001/03US Serial No. 10/601,314

Page 2

This Information Disclosure Statement is filed before the mailing date of a first office action on the merits.

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08A to the undersigned.

Dated: November 4, 2003

Respectfully submitted, COOLEY GODWARD LLP

Cooley Godward LLP ATTN: Patent Group Five Palo Alto Square 3000 El Camino Real Palo Alto, CA 94306-2155

Tel: (650) 843-5000 Fax: (650) 857-0663 By:

Sunil K. Singh Reg. No. 45,298

PTO/SB/08A (08-00)

Substitute for form 1449A/PTO				Complete if Known		
				Application Number	10/601,314	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	June 20, 2003	
				First Named Inventor	Thomas M. VAUGHN	
				Group Art Unit	1614	
(use as many sheets as necessary)			is necessary)	Examiner Name	Unassigned .	
Sheet	1	of	2	Attorney Docket Number	NASH-001/03US	

U.S. PATENT DOCUMENTS						
	U.S. Patent Document			Date of Publication of Cited		
Examiner Initials*	Cite No.1	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Document MM-DD-YYYY	
	A1	3,845,770		Theeuwes et al.	11-05-1974	
	A2	3,916,899		Theeuwes et al.	11-04-1975	
	A3	5,698,155	A	Grosswald et al.	12-16-1997	
	A4	3,228,789		Glassman	01-11-1966	
	A5	4,935,243		Borkan et al.	06-19-1990	
	A6 4,708,834			Cohen et al.	11-24-1987	
	A7	A7 4,840,966		Hara et al.	06-20-1989	
	A8	5,318,986		Hara et al.	06-07-1994	
	A9	5,879,730		Bouwens et al.	03-09-1999	
	A10	6,602,527		Slaga et al.	08-05-2003	
			<del> </del>			
	I	l		_1_		

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	. I FOIEIGH FAIGHL DOCUMENT				Date of Publication		
ilitiais	140.	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	T <sup>6</sup>	
		DE	19627344	A1	Vitasyn GMBH Entwicklund &Vertrieb Phar	03-09-1999		
		-						
			····					

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number.
<sup>2</sup> See attached Kinds of U.S. Patent Documents.

<sup>&</sup>lt;sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>&</sup>lt;sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

<sup>662389</sup> v1/PA

PTO/SB/08A (08-00)

			ATEM	& TRADER	Complete if Known	
Substi	Substitute for form 1449B/PTO		)	Application Number	10/601,314	
	INFORMATION DISCLOSURE			Filing Date	June 20, 2003	
INF				First Named Inventor	Thomas M. VAUGHN	
STA	TEMENT	BY A	PPLICANT	Group Art Unit	1614	
	use as many s	heets as	necessary)	Examiner Name	Unassigned	
Sheet	2	of	2	Attorney Docket Number	NASH-001/03US	

E	City	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	T <sup>2</sup>					
Examiner Initials*	Cite No. <sup>1</sup>	magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
	Cl	ALDERMAN D. A., "A Review of Cellulose Ethers in Hydrophilic Matrices for Oral Controlled-Release Dosage Forms," Int. J. Pharm. Tech. Prod. Mfr. 5(3):1-9, 1984						
	C2	BAMBA et al., "Release mechanisms in gelforming sustained release preparations," Int. J. Pharm. 2:307, 1979						
	C3	BERGE et al., J. Pharm. Sci. 66:1-19, 1977						
· · · · · · · · · · · · · · · · · · ·	C4	LEUNG et al., "Theaflavins in Black Tea and Catechins in Green Tea Are Equally Effective Antioxidants," J. Nutr. 131(9):2248-2251, 2001						
	C5	SARKAR et al., Biochem. Biophys. Res. Commun. 284(1):173-178, 2001						
	C6	VERMA et al., Drug Dev. Ind. Pharm. 26:695-708, 2000						
	C7	YOSHINO et al., Biol. Pharm. Bull. 17(1):146-149, 1994						
			, <u>.</u>					
			<del></del> -					

	ļ		
Examiner		Date	
Signature		Considered	i i

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number.
<sup>2</sup> Applicant is to place a check mark here if English language Translation attached.